SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
Type 2 diabetes mellitus (T2DM) is the cause of the development of diabetic nephropathy — a complication that determines the high degree of disability and mortality of such patients. Until recently, approaches to normalizing glucose levels did not have a significant possibility of influencing the ou...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2021-01-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327379334299648 |
|---|---|
| author | Vladimir V Salukhov Yurii Sh. Khalimov Sergey B. Shustov Sergey I. Popov |
| author_facet | Vladimir V Salukhov Yurii Sh. Khalimov Sergey B. Shustov Sergey I. Popov |
| author_sort | Vladimir V Salukhov |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is the cause of the development of diabetic nephropathy — a complication that determines the high degree of disability and mortality of such patients. Until recently, approaches to normalizing glucose levels did not have a significant possibility of influencing the outcome of kidney damage in diabetes. Type 2 sodium glucose cotransporter inhibitors (SGLT2) are a new class of glucose-lowering drugs that improve glycemic control due to an insulin-independent mechanism of action associated with increased urinary glucose excretion. The review provides an analysis of the results of studies on the assessment of nephroprotective actions — one of the pleiotropic actions of this drugs group. These materials show the properties of SGLT2 inhibitors to reduce the risk of developing and the progression of albuminuria, to save glomerular filtration rate, to reduce the frequency of end-stage renal disease and the need for renal replacement therapy in patients with T2DM. The article gives and analyzes the currently existing hypotheses of the mechanism of action of these glucose-lowering drugs. The risk of the most common renal complications with the use of SGLT2 inhibitors is considered. The practical aspects of the use of SGLT2 inhibitors in modern algorithms for the care of patients with T2DM are indicated, as well as the prospects for new randomized clinical trials. |
| format | Article |
| id | doaj-art-5c7f859deb01455f8bc09e299148dcde |
| institution | Kabale University |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-5c7f859deb01455f8bc09e299148dcde2025-08-20T03:47:53ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782021-01-0123547549110.14341/DM1212310849SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patientsVladimir V Salukhov0Yurii Sh. Khalimov1Sergey B. Shustov2Sergey I. Popov3S.M. Kirov Military Medical AcademyS.M. Kirov Military Medical AcademyS.M. Kirov Military Medical AcademyS.M. Kirov Military Medical AcademyType 2 diabetes mellitus (T2DM) is the cause of the development of diabetic nephropathy — a complication that determines the high degree of disability and mortality of such patients. Until recently, approaches to normalizing glucose levels did not have a significant possibility of influencing the outcome of kidney damage in diabetes. Type 2 sodium glucose cotransporter inhibitors (SGLT2) are a new class of glucose-lowering drugs that improve glycemic control due to an insulin-independent mechanism of action associated with increased urinary glucose excretion. The review provides an analysis of the results of studies on the assessment of nephroprotective actions — one of the pleiotropic actions of this drugs group. These materials show the properties of SGLT2 inhibitors to reduce the risk of developing and the progression of albuminuria, to save glomerular filtration rate, to reduce the frequency of end-stage renal disease and the need for renal replacement therapy in patients with T2DM. The article gives and analyzes the currently existing hypotheses of the mechanism of action of these glucose-lowering drugs. The risk of the most common renal complications with the use of SGLT2 inhibitors is considered. The practical aspects of the use of SGLT2 inhibitors in modern algorithms for the care of patients with T2DM are indicated, as well as the prospects for new randomized clinical trials.https://www.dia-endojournals.ru/jour/article/view/12123type 2 diabetes mellitusdiabetic nephropathyend-stage renal diseasealbuminuriaglomerular filtration ratenephroprotectiontype 2 sodium glucose cotransporter inhibitors |
| spellingShingle | Vladimir V Salukhov Yurii Sh. Khalimov Sergey B. Shustov Sergey I. Popov SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients Сахарный диабет type 2 diabetes mellitus diabetic nephropathy end-stage renal disease albuminuria glomerular filtration rate nephroprotection type 2 sodium glucose cotransporter inhibitors |
| title | SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients |
| title_full | SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients |
| title_fullStr | SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients |
| title_full_unstemmed | SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients |
| title_short | SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients |
| title_sort | sglt2 inhibitors and kidneys mechanisms and main effects in diabetes mellitus patients |
| topic | type 2 diabetes mellitus diabetic nephropathy end-stage renal disease albuminuria glomerular filtration rate nephroprotection type 2 sodium glucose cotransporter inhibitors |
| url | https://www.dia-endojournals.ru/jour/article/view/12123 |
| work_keys_str_mv | AT vladimirvsalukhov sglt2inhibitorsandkidneysmechanismsandmaineffectsindiabetesmellituspatients AT yuriishkhalimov sglt2inhibitorsandkidneysmechanismsandmaineffectsindiabetesmellituspatients AT sergeybshustov sglt2inhibitorsandkidneysmechanismsandmaineffectsindiabetesmellituspatients AT sergeyipopov sglt2inhibitorsandkidneysmechanismsandmaineffectsindiabetesmellituspatients |